Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) will report its financial results for the full-year ended December 31, 2023. The company focuses on developing AAV-based gene therapies for severe monogenic diseases of the CNS. A corporate update conference call is scheduled for March 19, 2024, at 4:30 PM Eastern Time.
03/14/2024 - 04:26 PM
DALLAS, March 14, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the full-year ended December 31, 2023, provide corporate and clinical updates and host a corporate update conference call on Tuesday, March 19, 2024, at 4:30 PM Eastern Time.
About Taysha Gene Therapies Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit www.tayshagtx.com .
Company Contact: Hayleigh Collins Director, Head of Corporate Communications, and Investor Relations Taysha Gene Therapies, Inc.hcollins@tayshagtx.com
Media Contact: Carolyn Hawley Inizio EvokeCarolyn.hawley@inizioevoke.com
When will Taysha Gene Therapies report its financial results for the full-year ended December 31, 2023?
Taysha Gene Therapies will report its financial results for the full-year ended December 31, 2023.
What is the focus of Taysha Gene Therapies?
Taysha Gene Therapies focuses on developing AAV-based gene therapies for severe monogenic diseases of the CNS.
When is the corporate update conference call scheduled?
The corporate update conference call is scheduled for March 19, 2024, at 4:30 PM Eastern Time.
Taysha Gene Therapies Inc
TSHA Rankings
#681 Ranked by Stock Gains
TSHA Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology
About TSHA
taysha gene therapies, inc., a gene therapy company, develops adeno-associated virus based gene therapies for the treatment of monogenic diseases of the central nervous system. it primarily develops tsha-101 for the treatment of gm2 gangliosidosis; tsha-118 for the treatment of cln1 disease; tsha-102 for the treatment of rett syndrome; tsha-103 for the treatment of slc6a1 haploinsufficiency disorder; and tsha-104 for the treatment for surfeit locus 1 deficiency. the company also has strategic partnership with the university of texas southwestern medical center to develop and commercialize transformative gene therapy treatments. taysha gene therapies, inc. was founded in 2019 and is based in dallas, texas.